The Powell Perspective

National homebuilder Toll Brothers opens Bethany Farms in Simpsonville, tapping into the area's hot luxury market with customizable homes and amenities.

As Leverage Shares by Themes launches seven new 2x daily leveraged ETFs, a look at the high-stakes game of amplified returns and the risks for investors.

An international expert panel endorses an advanced wound therapy, potentially revolutionizing patient recovery and boosting a key player in the med-tech market.

The CT Plan selects DataCT as its independent administrator, a critical step in a sweeping SEC-mandated overhaul of market data set for 2027.

The iGaming supplier launches 80 exclusive games in Brazil's new regulated market, a strategic move to capture growth in Latin America's largest economy.

Subsea 7 has landed a contract worth up to $300M for Chevron's Gorgon Stage 3 project, reinforcing its key role in Australia's deepwater energy sector.

Odysight.ai's new sensors offer a live video feed from inside hot, oil-filled machinery, a breakthrough poised to transform industrial predictive maintenance.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

A key 2026 legal forum reveals the DOJ's expanding False Claims Act focus, putting cybersecurity non-compliance and private equity investors on notice.

Beyond the dividend payout, Cherry Hill Mortgage's strategy reveals a deeper pivot towards digital innovation, balancing high yields with new frontiers of risk.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Lion Group's $8M Bitcoin purchase highlights a growing corporate trend, but a plunging stock price reveals the immense risks of digital asset treasuries.

A new class of AI-driven blood tests can detect lung cancer recurrence years before imaging, shaking up patient care and the multi-billion dollar diagnostics market.

After a difficult post-IPO year, Amaze Holdings is shedding debt and leveraging AI to redefine creator monetization. Is its new strategy the future?

Streamex's $12.2M stake in Empress Royalty isn't just a purchase; it's a blueprint for tokenizing real-world assets and reshaping commodity markets.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

Match Group bets big on the future of dating, spinning out an AI venture while a new CEO steers Hinge toward its projected $1 billion revenue goal.

Annaly Capital's consistent dividend payout raises key questions about strategy, risk, and the future of the mortgage REIT sector. What does it signal?

A hedge fund's 2.34% derivatives stake in Alphawave IP suggests a major acquisition by Qualcomm, highlighting a high-stakes battle for key chip IP.